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Abstract
In addition to both the a1 adrenergic receptor and N-methyl-D-aspartate (NMDA) receptor antagonists, ifenprodil binds to
the sigma receptor subtypes 1 and 2. In this study, we examined the effects of ifenprodil on nerve growth factor (NGF)-
induced neurite outgrowth in PC12 cells. Ifenprodil significantly potentiated NGF-induced neurite outgrowth, in a
concentration-dependent manner. In contrast, the a1 adrenergic receptor antagonist, prazosin and the NMDA receptor
NR2B antagonist, Ro 25-6981 did not alter NGF-induced neurite outgrowth. Potentiation of NGF-induced neurite outgrowth
mediated by ifenprodil was significantly antagonized by co-administration of the selective sigma-1 receptor antagonist, NE-
100, but not the sigma-2 receptor antagonist, SM-21. Similarly, ifenprodil enhanced NGF-induced neurite outgrowth was
again significantly reduced by the inositol 1,4,5-triphosphate (IP3) receptor antagonists, xestospongin C and 2-
aminoethoxydiphenyl borate (2-APB) treatment. Furthermore, BAPTA-AM, a chelator of intracellular Ca
2+, blocked the
effects of ifenprodil on NGF-induced neurite outgrowth, indicating the role of intracellular Ca
2+ in the neurite outgrowth.
These findings suggest that activation at sigma-1 receptors and subsequent interaction with IP3 receptors may mediate the
pharmacological effects of ifenprodil on neurite outgrowth.
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Introduction
Recent findings reveal that the sigma-1 receptor is a novel
endoplasmic reticulum (ER) chaperone, which regulates a variety
of cellular functions, such as inositol 1,4,5-triphosphate (IP3)
receptor-mediated Ca
2+ signaling, ion channel firing, protein
kinase location/activation, cellular redox, neurotransmitter re-
lease, inflammation, cellular differentiation, neuronal survival and
synaptogenesis [1–4]. Accumulating evidence suggests that the
sigma-1 receptor plays an important role in neuronal plasticity, a
process implicated in the pathophysiology of neuropsychiatric
diseases, such as Alzheimer’s disease, major depressive disorder,
and schizophrenia [1–15].
PC12 cells, a cell line derived from a pheochromocytoma of rat
adrenal medulla, have been widely used as a model system for
nerve growth factor (NGF)-induced neuronal differentiation. It has
been reported that sigma-1 receptor agonists, such as (+)-
pentazocine, imipramine, fluvoxamine, donepezil, and dehydro-
epiandrosterone-sulfate (DHEA-S), potentiate NGF-induced neu-
rite outgrowth in PC12 cells, and that the selective sigma-1
receptor antagonist NE-100 significantly attenuated the efficacy of
these drugs, suggesting a role for sigma-1 receptors in neuronal
plasticity [16–18]. However, the precise cellular mechanisms of
the sigma-2 receptor are unclear, as this receptor has not yet been
cloned.
Ifenprodil (CerocralH) has been used as a cerebral vasodilator in
a limited number of countries, including Japan and France. It acts
as a prototypical antagonist of the N-methyl-D-aspartate (NMDA)
receptor, NR2B subunit [19,20]. As well as binding to the a1
adrenergic receptor and NMDA receptor antagonists, ifenprodil
also binds to sigma-1 and sigma-2 receptors [21–23]. Despite the
current knowledge, there are no reports describing the effects of
ifenprodil on neuronal plasticity. In addition, it remains unclear
whether ifenprodil acts as an agonist or antagonist on the sigma
receptor subtypes.
In this study, we examined whether ifenprodil could potentiate
NGF-induced neurite outgrowth in PC12 cells. We also examined
the roles of sigma receptor subtypes 1 and 2, the a1 adrenergic
receptor, and the NR2B subtype of the NMDA receptor in
ifenprodil mediated, NGF-induced neurite outgrowth. Moreover,
we looked at the role of IP3 receptors on NGF-induced neurite
outgrowth by ifenprodil, since sigma-1 receptor associated
neuronal plasticity utilizes IP3 receptors [1,2,17,18].
Results
Effects of ifenprodil on NGF-induced neurite outgrowth
Ifenprodil (0.1, 1.0, or 10 mM) increased the number of cells
with neurite outgrowth in NGF (2.5 ng/ml) treated PC12 cells, in
a concentration-dependent manner (Figure 1). MAP-2 and GAP-
43 immunocytochemistry have been used as a useful indicator of
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37989neuronal differentiation in PC12 cells [17,18,24]. MAP-2 and
GAP-43 immunocytochemistry revealed that the addition of
ifenprodil (10 mM) increased the number of cells with neurite
outgrowth in PC12 cells compared with controls (Figure 2).
Role of sigma-1 receptor, but not a1 adrenergic receptor
and the NMDA receptor, in the mechanisms of
potentiation of NGF-induced neurite outgrowth by
ifenprodil
In order to determine the role of sigma receptor subtypes, we
examined the effects of NE-100 (a sigma-1 receptor antagonist)
[25] and SM-21 (a sigma-2 receptor antagonist) [26] on the
potentiation of NGF-induced neurite outgrowth by ifenprodil
(10 mM). ANOVA analysis revealed that data from the eight
groups differed significantly (F (7,64)=17.46, p,0.001)(Figure 1).
Post hoc Bonferroni/Dunn test results indicated that co-adminis-
tration of NE-100 (1.0 mM) with ifenprodil (10 mM) significantly
reduced the potentiation of NGF-induced neurite outgrowth
(Figure 1). However, co-administration of SM-21 (10 mM) with
ifenprodil (10 mM) did not affect the potentiation of NGF-induced
neurite outgrowth (Figure 1). Administration of NE-100 (1.0 mM)
or SM-21 (10 mM) alone did not alter NGF-induced neurite
outgrowth in PC12 cells (Figure 1).
To assess the role of the a1 adrenergic receptor and the NMDA
receptor, NR2B subunit, we examined the effects of the selective
a1 adrenergic receptor antagonist prazosin and the selective
NR2B antagonist Ro 25-6981 [27] on the potentiation of NGF-
induced neurite outgrowth by ifenprodil (10 mM). Neither the a1
adrenergic receptor antagonist, prazosin (10 mM) nor the NR2B
antagonist Ro 25-6981 (10 mM) altered the number of cells with
NGF induced neurite outgrowth (Figure 3), suggesting that these
receptors do not play a role in the mechanisms of ifenprodil
potentiation of neurite outgrowth.
Role of IP3 receptor and intracellular Ca
2+ in the
mechanisms of potentiation of NGF-induced neurite
outgrowth by ifenprodil
Next, we examined the effects of IP3 receptor antagonists,
xestospongin C (a selective, reversible membrane-permeable
inhibitor of IP3 receptors) [28] and 2-APB (a membrane-
permeable IP3 receptor antagonist) [29,30] on ifenprodil poten-
tiation of neurite outgrowth. ANOVA analysis revealed significant
differences among the four groups (F (3,20)=44.02, p,0.001)
(Figure 4A). Co-administration of xestospongin C (1.0 mM)
significantly reduced neurite outgrowth by ifenprodil (10 mM)
(Figure 4A). ANOVA analysis revealed that the data among the
Figure 1. Effects of ifenprodil with or without sigma receptor antagonists on NGF-induced neurite outgrowth in PC12 cells. In the
presence of NGF (2.5 ng/ml), ifenprodil (0.1, 1.0, or 10 mM) with or without NE-100 (1.0 mM; a sigma-1 receptor antagonist), or SM-21 (10 mM; a sigma-
2 receptor antagonist) were incubated with PC12 cells. Four days after incubation with test drugs, morphometric analysis was performed. The data
show the mean 6 SEM (n=6–18). **P,0.01, ***p,0.001 when compared to the control group.
###p,0.001 when compared to the ifenprodil
(10 mM)-treated group.
doi:10.1371/journal.pone.0037989.g001
Figure 2. Representative photographs of MAP-2 and GAP-43
immunocytochemistry in PC12 cells. In the presence of NGF
(2.5 ng/ml), vehicle control or ifenprodil (10 mM) were incubated with
PC12 cells. Four days after incubation with test drugs, MAP-2 and GAP-
43 immunocytochemistry was performed. Arrowhead shows the cells
with neurite outgrowth.
doi:10.1371/journal.pone.0037989.g002
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(Figure 4B). Co-administration of 2-APB (100 mM) significantly
reduced neurite outgrowth by ifenprodil (10 mM) (Figure 4B).
Administration of xestospongin C (1.0 mM) or 2-APB (100 mM)
alone did not alter NGF-induced neurite outgrowth in PC12 cells
(Figure 4A and 4B).
To assess the role of intracellular Ca
2+ in the cells, we examined
the effects of the BAPTA-AM, a chelator of intracellular Ca
2+
[31,32], on the potentiation of NGF-induced neurite outgrowth by
ifenprodil (10 mM). ANOVA analysis revealed significant differ-
ences among the four groups (F (3,20)=56.06, p,0.001)
(Figure 5). Administration of BAPTA-AM (5.0 mM) significantly
reduced neurite outgrowth by ifenprodil (10 mM) (Figure 5). In
addition, BAPTA-AM (5.0 mM) alone significantly blocked NGF-
induced neurite outgrowth. These findings suggest that the
intracellular Ca
2+ plays an important role in the mechanism of
NGF-induced neurite outgrowth.
Discussion
In this study, we found that ifenprodil potentiated NGF-induced
neurite outgrowth in PC12 cells, and that the effects of ifenprodil
Figure 3. Effects of a1 adrenergic receptor antagonist and
NR2B antagonist on NGF-induced neurite outgrowth in PC12
cells. In the presence of NGF (2.5 ng/ml), vehicle, prazosin (10 mM), or
Ro 25-6981 (10 mM) were incubated with PC12 cells. Four days after
incubation with test drugs, morphometric analysis was performed. The
data show the mean 6 SEM (n=6). NS: Not significance.
doi:10.1371/journal.pone.0037989.g003
Figure 4. Effects of IP3 receptor antagonists on NGF-induced neurite outgrowth in PC12 cells. (A): In the presence of NGF (2.5 ng/ml),
vehicle, ifenprodil (10 mM), ifenprodil (10 mM)+xestospongin C (1.0 mM), xestospongin C (1.0 mM) were incubated with PC12 cells. (B): In the presence
of NGF (2.5 ng/ml), vehicle, ifenprodil (10 mM), ifenprodil (10 mM)+2-APB (100 mM), or 2-APB (100 mM) were incubated in PC12 cells. Four days after
incubation with test drugs, morphometric analysis was performed. The data show the mean 6 SEM (n=6). ***p,0.001 when compared with the
ifenprodil (10 mM)-treated group.
doi:10.1371/journal.pone.0037989.g004
Figure 5. Effects of BAPTA-AM on potentiation of NGF-induced
neurite outgrowth by ifenprodil. In the presence of NGF (2.5 ng/
ml), vehicle, ifenprodil (10 mM), ifenprodil (10 mM)+BAPTA-AM (5.0 mM),
or BAPTA-AM (5.0 mM) were incubated with PC12 cells. Four days after
incubation with test drugs, morphometric analysis was performed. The
data show the mean 6 SEM (n=6). ***p,0.001 when compared to the
control group.
###p,0.001 when compared to the ifenprodil (10 mM)-
treated group.
doi:10.1371/journal.pone.0037989.g005
Ifenprodil and Neurite Outgrowth
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e37989were blocked by treatment with the selective sigma-1 receptor
antagonist, NE-100 [25], but not the sigma-2 receptor antagonist,
SM-21 [26]. Furthermore, the effects of ifenprodil were also
blocked by treatment with two IP3 receptor antagonists. This is a
first paper demonstrating a role for sigma-1 and IP3 receptors in
ifenprodil mediated potentiation of NGF-induced neurite out-
growth. Recently, we reported that sigma-1 receptor agonists such
as SA4503, fluvoxamine, DHEA-S and donepezil, could potenti-
ate NGF-induced neurite outgrowth in PC12 cells, and that this
potentiation could be antagonized by co-administration of NE-100
or xestospongin C [17,18]. Taken together, it is likely that both
sigma-1 and IP3 receptors are involved in the potentiation of
NGF-induced neurite outgrowth by ifenprodil. In contrast, the
sigma-2 receptor antagonist SM-21, failed to alter this enhanced
outgrowth, suggesting a lack of involvement in this process.
It is likely that sigma-1 receptors interact with IP3 receptors on
the ER, as well as regulate intracellular Ca
2+ release. Recently,
Hayashi and Su [1] identified sigma-1 receptors as novel, ligand-
operated chaperones that specifically target the mitochondrion-
associated ER membrane. When the sigma-1 receptor forms a
complex with the ER chaperone, immunoglobulin heavy chain
binding protein, BiP, activity is minimized. In contrast, when
dissociated from BiP, the sigma-1 receptor exerts maximum
chaperone activity. In addition, several synthetic agonists of the
sigma-1 receptor promote its dissociation from BiP, thus stimu-
lating the chaperone activity of this receptor [1–3]. In this study,
we found that the cell-permeable Ca
2+ chelator BAPTA-AM
blocked the effects of ifenprodil on NGF-induced neurite
outgrowth. In addition, BAPTA-AM alone blocked NGF-induced
neurite outgrowth in PC12 cells, consistent with previous reports
[31,32]. These findings suggest that the intracellular Ca
2+ plays an
important role in the neurite outgrowth mediated by NGF.
Therefore, it is likely that the therapeutic activity of sigma-1
receptor agonists, such as ifenprodil, could be mediated through
modulation of intracellular Ca
2+ signaling.
Recently, we reported that ifenprodil was effective in treating
emotional incontinence in patients with vascular dementia
(Kishimoto et al., submitted), and flashbacks in female post-
traumatic stress disorder (PTSD) patients, with a history of
childhood sexual abuse [33]. To our knowledge, this represents the
first demonstration of a beneficial effect for ifenprodil in these
groups of patients. However, the precise mechanisms underlying
the therapeutic effects of ifenprodil are currently unclear. Given
the role of sigma-1 receptors in modulating neurite outgrowth, it is
likely that these receptors may at least play a partial a role in the
beneficial effects of ifenprodil seen in these patients, although
further detailed studies are needed. Accumulating evidence
suggests a role for glutamatergic neurotransmission via the NMDA
receptors, in the pathophysiology of PTSD [34,35]. With its high
affinity for both the NMDA and sigma-1 receptors, it is likely that
ifenprodil acts on these receptors to alleviate emotional inconti-
nence as well as flashbacks in these patients ([33], Kishimoto et al.,
submitted). Nonetheless, further large scale clinical studies will be
needed to further support this initial finding.
In conclusion, this study suggests that ifenprodil can potentiate
NGF-induced neurite outgrowth in PC12 cells, and that both the
sigma-1 receptor and IP3 receptors play a role in the mechanisms
of this potentiation. Therefore, it is likely that stimulation at sigma-
1 receptors may be involved in the pharmacological action of
ifenprodil in humans.
Materials and Methods
Drugs
The drugs listed here were used in these experiments: ifenprodil
tartrate and prazosin (Sigma-Aldrich Co., Ltd., St. Louis, MO,
USA), Ro 25-6981 maleate ((aR,bS)-a-(4-Hydroxyphenyl)-b-meth-
yl-4-(phenylmethyl)-1-piperidinepropanol maleate) and SM-21
maleate ((6)-tropanyl 2-(4-chlorophenoxy)butanoate maleate)
(Tocris Bioscience, Bristol, UK), xestospongin C (Wako Pure
Chemical Industries, Tokyo, Japan), 2-aminoethoxydiphenyl
borate (2-APB) (Calbiochem-Novabiochem Co., San Diego, CA,
USA), NGF (Alomone Labs. Ltd., Jerusalem, Israel), BAPTA-AM,
1,2-bis(2-aminophenoxy)ethane-N,N,N9,N9-tetraacetic acid tetra-
kis) acetoxymethyl ester, (Dojindo Molecular Technologies, Inc.,
Kumamoto, Japan). The selective sigma-1 receptor antagonist NE-
100 was synthesized in our laboratory. Other compounds were
purchased from commercial sources.
Cell culture and quantification of neurite outgrowth
PC12 cells (RIKEN Cell Bank, Tsukuba, Japan) were cultured
at 37uC under 5% CO2 with Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 5% heat-inactivated fetal bovine
serum (FBS), 10% heat-inactivated horse serum, 1% penicillin and
1% streptomycin. The medium was changed two or three times a
week. PC12 cells were plated onto 24-well tissue culture plates
coated with poly-D-lysine/laminin. Cells were plated at relatively
low density (0.25610
4 cells/cm
2) in DMEM containing 0.5% FBS,
1% penicillin and 1% streptomycin. Medium containing a
minimal level of serum (0.5% FBS) was used since serum contains
steroid hormones which bind to sigma-1 receptors [16–18]. In a
previous paper, we found that NGF at 2.5–40 ng/ml promoted
neurite outgrowth in PC12 cells, in a concentration-dependent
manner [17]. Therefore, NGF at a concentration of 2.5 ng/ml
was used in this study. Twenty-four hours after plating, the
medium was replaced with DMEM containing 0.5% FBS, 1%
penicillin and 1% streptomycin with NGF (2.5 ng/ml), with or
without ifenprodil (0.1, 1.0 or 10 mM), prazosin (a1 adrenergic
receptor antagonist; 10 mM), Ro 25-6981 (NMDA receptor NR2B
antagonist; 10 mM), NE-100 (sigma-1 receptor antagonist;
1.0 mM), SM-21 (sigma-2 receptor antagonist; 10 mM), xestospon-
gin C (IP3 receptor antagonist; 1.0 mM), 2-APB (IP3 receptor
antagonist; 100 mM) or BAPTA-AM (a chelator of intracellular
Ca
2+; 5.0 mM).
Four days after incubation with NGF (2.5 ng/ml) and test
drugs, morphometric analysis was performed on digitized images
of live cells, taken under phase contrast illumination, using an
inverted microscope linked to a camera. Images of three fields per
well were taken, with an average of 100 cells per field. The
number of differentiated cells was determined by visually
examining the field, and counting cells with at least one neurite
equivalent to the length of a cell body diameter. This number was
expressed as a percentage of the total number of cells in the field.
Counting was performed in a blind manner as described
previously [17,18,36,37].
MAP-2 and GAP-43 immunocytochemistry
Cells were fixed for 30 min at room temperature with 4%
paraformaldehyde, then permeabilized with 0.2% Triton, and
blocked with 5% normal goat serum, in 0.1 M phosphate-buffer
saline containing 0.1% Tween-20 for 2 h. This was to reduce non-
specific binding. Cells were incubated overnight at 4uC with anti-
microtubule associated protein 2 (MAP-2) antibodies (1:500
dilution in blocking solution; Chemicon International Inc.,
Temecula, CA, USA) or rabbit polyclonal antibody against
Ifenprodil and Neurite Outgrowth
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solution; Abcam, Cambridge, MA, USA). Immunolabels were
visualized using secondary antibodies conjugated to Alexa-488
(1:1000; Invitrogen Corporation, Carlsbad, CA, USA).
Statistical analysis
Data are expressed as the mean 6 standard error of the mean
(S.E.M.). Statistical analysis was performed by one-way analysis of
variance (ANOVA) and post hoc Bonferroni/Dunn testing. Values
of p less than 0.05 were considered statistically significant.
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